About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 452709, 7 pages
http://dx.doi.org/10.1155/2013/452709
Clinical Study

Determinants of Thyrotoxic Cardiomyopathy Recovery

1Departamento de Ecocardiografía, Hospital de Especialidades de la Ciudad de México, Avenida Tláhuac 4866 Del Iztapalapa, 09700 México, DF, Mexico
2Departamento de Investigación Sociomédica, Instituto Nacional de Cardiología “Ignacio Chávez,” Juan Badiano No. 1, Col. Sección XVI, Del. Tlalpan, 14080 México, DF, Mexico
3Departamento de Endocrinología, Hospital Dr. Enrique Cabrera, Avenida Centenario Esquina Prolongación 5 de Mayo, Col ExHacienda de Tarango, Del Alvaro Obregón, 01618 México, DF, Mexico

Received 4 April 2013; Revised 14 June 2013; Accepted 18 July 2013

Academic Editor: Jeffrey L. Anderson

Copyright © 2013 Lucia Oliveros-Ruiz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The purpose was to evaluate the effect of the disease duration prior to treatment, thyroid hormones level, or both on the reversibility of dilated cardiomyopathy. Between January 2006 and December 2010, a longitudinal study with a 6 months follow-up was carried on. One hundred and seventy patients with hyperthyroidism were referred to the cardiologist, and 127 had a 6 months followup after antithyroid treatment and were evaluated by echocardiography. Dilated cardiomyopathy reversibility criteria were established according to echocardiographic parameters. Complete reversibility existed when all parameters were met, partial reversibility when LVEF was ≥55% plus two or three other parameters, and no reversibility when LVEF was ≤55% regardless of other parameters. The results showed that echocardiography parameters related to the regression of myocardial mass were associated with a disease duration shorter than 10.38 months. This was the main predictive variable for reversal of dilated cardiomyopathy, followed by β-blocker treatment, and the last predictive variable was the serum level of free triiodothyronine. This study showed that the effect on the myocardium related to thyrotoxicosis was associated with the disease duration before treatment.